ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1260

Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis

Irina Gessl1, Mihaela Popescu2, Gabriela supp3, Thomas Deimel1, Paul Studenic1, Martina Durechova3, michael zauner3, Josef Smolen1 and Peter Mandl1, 1Medical University of Vienna, Vienna, Austria, 2Department of Rheumatology, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada, 3Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

Meeting: ACR Convergence 2022

Keywords: Imaging, Outcome measures, pain, Psoriatic arthritis, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Imaging of Rheumatic Diseases Poster

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: In inflammatory arthritis swelling is regarded as a sign of synovitis and is associated with radiographic progression. However, the association of tenderness with radiographic progression is not clear. The aim of this study was to assess the predictive value of tenderness alone and with consideration of sonographic signs for synovitis, disease duration and baseline radiographic damage for subsequent radiographic progression in rheumatoid arthritis (RA) and psoriatic arthritis (PsA).

Methods: Clinical and sonographic (grey scale (GS) and power Doppler (PD)) examination of 22 joints of the hand were performed cross-sectionally in consecutive patients with RA and PsA with at least one tender joint. Radiographs were scored for erosions and joint space narrowing (JSN) at inclusion and radiographic progression of each joint was assessed after 2 years. The impact of tenderness on progression was analyzed in non-swollen joints for RA and PsA separately with logistic regression analyses. As a second step, the association of PD, GS, disease duration, C-reactive protein, baseline erosions and JSN and global joint counts with subsequent structural damage was assessed using univariate logistic regression in tender non-swollen joints again on the joint level.

Results: We included 1207 joints in 54 RA patients and 396 joints in 18 PsA patients. Tenderness was associated with subsequent radiographic progression in non-swollen joints in PsA (OR 3.44, 95%CI 1.78-6.62, p< 0.01) but not in RA (OR 1.60, 95% CI 0.99-2.48, p=0.55) (Figure 1). In tender non-swollen joints in RA patients, PD (OR 3.74, 95% CI 1.10-13.30, p=0.04) and baseline erosions (OR 4.42, 95% CI 1.22-15.95, p=0.02) had a significant impact on radiographic progression. In PsA patients, PD (OR 8.46, 95% CI 1.72-41.72, p< 0.01), baseline erosions (OR 6.71, 95% CI 1.43-31.39, p=0.02), baseline JSN (OR 7.27, 95% CI 1.47-35.89, p=0.02) and SJC (OR 1.26, 95%CI 1.07-1.48, p< 0.01) were associated with radiographic progression.

Conclusion: Our findings indicate that tenderness in non-swollen joints is associated with subsequent radiographic progression in PsA, while in RA it is a risk factor for radiographic progression only in the presence of additional factors, such as sonographic signs for synovitis.

Supporting image 1

Figure 1. The proportion of joints with progression in tender non-swollen and non-tender non-swollen joints in patients with rheumatoid and psoriatic arthritis; NTNS: non-tender non-swollen; TNS: tender non-swollen

Supporting image 2

Figure 2. The proportion of tender non-swollen joints with radiographic progression in patients with rheumatoid arthritis depending on power Doppler signs for synovitis (A), disease duration (B), erosions (C) and JSN (D) at baseline x-ray and difference of baseline SJC (E) and TJC (F) of joints with and without subsequent progression. BL, baseline; early, early rheumatoid arthritis (<3 years disease duration), JSN, joint space narrowing; long-standing, long-standing rheumatoid arthritis (>5 years disease duration); PD, power Doppler; SJC, swollen joint count; TJC, tender joint count.

Supporting image 3

Figure 3. The proportion of tender non-swollen joints with progression in patients with psoriatic arthritis depending on power Doppler signs for synovitis (A), disease duration (B), erosions (C) and JSN (D) at baseline x-ray and difference of baseline 66 SJC (E) and 68 TJC (F) of joints with and without subsequent progression. BL, baseline; early, early psoriatic arthritis (<3 years disease duration), JSN, joint space narrowing; long-standing, long-standing psoriatic arthritis (>5 years disease duration); PD, power Doppler; SJC, swollen joint count; TJC, tender joint count.


Disclosures: I. Gessl, Eli Lilly, Boehringer-Ingelheim, Gilead; M. Popescu, None; G. supp, None; T. Deimel, None; P. Studenic, AbbVie/Abbott; M. Durechova, None; m. zauner, None; J. Smolen, AbbVie, AstraZeneca, Eli Lilly, Novartis, Amgen, Bristol Myers Squibb, Galapagos-Gilead, Janssen, Merck-Sharp-Dohme, Novartis-Sandoz, Pfizer, Roche-Chugai, Samsung, UCB; P. Mandl, None.

To cite this abstract in AMA style:

Gessl I, Popescu M, supp G, Deimel T, Studenic P, Durechova M, zauner m, Smolen J, Mandl P. Tenderness and Radiographic Progression in Rheumatoid Arthritis and Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/tenderness-and-radiographic-progression-in-rheumatoid-arthritis-and-psoriatic-arthritis-2/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tenderness-and-radiographic-progression-in-rheumatoid-arthritis-and-psoriatic-arthritis-2/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology